GlassScriptPhysician profile
William A Lee
NPI 1619960705
$11,284.66
in general payments reported to CMS, 2019-2025
41 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,609 · 2020: $917 · 2021: $2,695 · 2022: $1,366 · 2023: $1,440 · 2024: $1,566 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,697.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,581.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,398.62 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,370.84 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,365.41 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,169.75 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $729.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $521.24 | 2019-2025 | Repatha, Evenity, Krystexxa |
| Janssen Pharmaceuticals, INC | $356.52 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $338.35 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $306.16 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $237.61 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $224.66 | 2020-2021 | |
| Abbott Laboratories | $178.96 | 2019-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $168.76 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $120.04 | 2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $118.35 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $116.65 | 2023 | Quviviq |
| Pfizer INC. | $108.60 | 2019-2025 | |
| Allergan, INC. | $91.67 | 2019-2020 | |
| Amarin Pharma, INC. | $84.34 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $77.74 | 2019-2022 | |
| Medtronic, INC. | $63.13 | 2023 | Kyphon Express II Kyphopak Tray |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.51 | 2024-2025 | Lifevest |
| Arbor Pharmaceuticals, INC. | $49.92 | 2019-2021 | |
| Lundbeck LLC | $48.39 | 2020-2021 | |
| Humacyte Global, INC. | $46.65 | 2025 | Symvess |
| Inari Medical, INC. | $43.22 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Dexcom, INC. | $41.22 | 2024-2025 | Dexcom G6 Transmitter |
| Phadia US INC. | $31.85 | 2019-2025 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $30.98 | 2021-2022 | |
| Dynavax Technologies Corporation | $25.50 | 2022 | |
| Eisai INC. | $23.12 | 2020 | |
| Astellas Pharma US INC | $20.32 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.21 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $18.98 | 2021 | |
| Shockwave Medical, INC | $18.96 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Dermira, INC. | $17.45 | 2020 | |
| Apria Healthcare LLC | $15.67 | 2021 | |
| Intra-Sana Laboratories | $15.24 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Alnylam Pharmaceuticals INC. | $14.07 | 2024 | Onpattro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.